<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>BMC Clinical Pathology - Most viewed articles</title>
		<link>http://www.biomedcentral.com/bmcclinpathol/mostviewed/</link>
		<description>Most viewed articles in last 30 days from BMC Clinical Pathology (ISSN 1472-6890) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
         <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6890/8/7"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6890/7/3"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6890/8/3"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6890/8/5"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6890/8/6"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6890/8/1"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6890/2/2"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6890/7/8"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6890/8/4"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6890/6/4"/>			    
            
            </rdf:Seq>
        </items>
    </channel>
    
		<item rdf:about="http://www.biomedcentral.com/1472-6890/8/7">
            
            <title>Pathology of rituximab-induced Kaposi sarcoma flare</title>
			<description>Background:
Kaposi sarcoma (KS) flare may occur following therapy with corticosteroids, as part of the immune reconstitution inflammatory syndrome seen with highly active antiretroviral therapy (HAART), and after rituximab therapy. The exact mechanism responsible for iatrogenic KS flare is unclear.
Methods:
A case of AIDS-associated cutaneous KS flare following rituximab therapy was compared to similar controls by means of immunohistochemistry using vascular makers (CD34, CD31), monoclonal antibodies to Human Herpesvirus 8 (HHV8) gene products (LNA-1, K5), as well as B-lymphocyte (CD20) and T-lymphocyte (CD3, CD4, CD8) markers.
Results:
CD20+ B-cell depletion with rituximab in KS flare occurred concomitantly with activation of the HHV8 immediate early gene protein K5. KS flare in this patient was successfully treated with liposomal doxorubicin and valganciclovir.
Conclusion:
Rituximab-induced KS flare appears to be related to HHV8 activation. Effective management of iatrogenic KS flare therefore depends upon the control of HHV8 viremia in conjunction with specific chemotherapy for KS.</description>
			<link>http://www.biomedcentral.com/1472-6890/8/7</link>		
			<dc:creator>Liron Pantanowitz, Klaus Fr&#252;h, Sharon Marconi, Ashlee V Moses and Bruce J Dezube</dc:creator>
			<dc:source>BMC Clinical Pathology 2008, 8:7</dc:source>
			<dc:subject>Number of accesses: 450</dc:subject>
			<dc:date>2008-07-23</dc:date>
			<dc:identifier>doi:10.1186/1472-6890-8-7</dc:identifier>
			
			
							
					<prism:publicationName>BMC Clinical Pathology</prism:publicationName>
					
			
							
					<prism:issn>1472-6890</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>7</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-23</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6890/7/3">
            
            <title>Rosai-Dorfman Disease: A previously unreported association with Sickle Cell Disease</title>
			<description>Background:
Rosai-Dorfman Disease is an uncommon benign systemic histio-proliferative disease. This is the first time the disease, although more common in people of African descent, is described in association with Sickle cell disease.Case presentationA Nigerian boy born started a complex medical history with post-natal anemia of unknown origin. Subsequently he was diagnosed with Sickle Cell Anemia (Hb SS). At age 3 during a routine review, he was noted to have generalised massive lymphadenopathy. He had further reoccurrences of this lymphadenopathy, but investigations did not reveal the cause until age five. At this point, because of the progressive lymph node enlargement, a biopsy was performed, and he was diagnosed with Rosai-Dorfman Disease. Since that time, the child has had further episodes of intermittent massive lymphadenopathy, particularly associated with Sickle Crisis. His medical history has been further complicated by development of complications from Sickle Cell Disease, cardiomyopathy and an autoimmune hemolytic anemia with multiple alloantibodies.
Conclusion:
This case for the first time presents the co-existence of two diseases, of increased prevalence in those of African descent, but to date not described in the literature to occur concurrently.</description>
			<link>http://www.biomedcentral.com/1472-6890/7/3</link>		
			<dc:creator>Claire Stebbing, Jon van der Walt, Ghada Ramadan and Baba Inusa</dc:creator>
			<dc:source>BMC Clinical Pathology 2007, 7:3</dc:source>
			<dc:subject>Number of accesses: 330</dc:subject>
			<dc:date>2007-04-02</dc:date>
			<dc:identifier>doi:10.1186/1472-6890-7-3</dc:identifier>
			
			
							
					<prism:publicationName>BMC Clinical Pathology</prism:publicationName>
					
			
							
					<prism:issn>1472-6890</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>3</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-04-02</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6890/8/3">
            
            <title>Testing for hereditary thrombophilia: a retrospective analysis of testing referred to a national laboratory</title>
			<description>Background:
Predisposition to venous thrombosis may be assessed through testing for defects and/or deficiencies of a number of hereditary factors. There is potential for confusion about which of these tests are appropriate in which settings. At least one set of recommendations has been published to guide such testing, but it is unclear how widely these have been disseminated.
Methods:
We performed a retrospective analysis of laboratory orders and results at a national referral laboratory to gain insight into physicians' ordering practices, specifically comparing them against the ordering practices recommended by a 2002 College of American Pathologists (CAP) consensus conference on thrombophilia testing. Measurements included absolute and relative ordering volumes and positivity rates from approximately 200,000 thrombophilia tests performed from September 2005 through August 2006 at a national reference laboratory. Quality control data were used to estimate the proportion of samples that may have been affected by anticoagulant therapy. A sample of ordering laboratories was surveyed in order to assess potential measurement bias.
Results:
Total antigen assays for protein C, protein S and antithrombin were ordered almost as frequently as functional assays for these analytes. The DNA test for factor V Leiden was ordered much more often than the corresponding functional assay. In addition, relative positivity rates coupled with elevations in prothrombin time (PT) in many of these patients suggest that these tests are often ordered in the setting of oral anticoagulant therapy.
Conclusion:
In this real-world setting, testing for inherited thrombophilia is frequently at odds with the recommendations of the CAP consensus conference. There is a need for wider dissemination of concise thrombophilia testing guidelines.</description>
			<link>http://www.biomedcentral.com/1472-6890/8/3</link>		
			<dc:creator>Brian R Jackson, Kyland Holmes, Amit Phansalkar and George M Rodgers</dc:creator>
			<dc:source>BMC Clinical Pathology 2008, 8:3</dc:source>
			<dc:subject>Number of accesses: 296</dc:subject>
			<dc:date>2008-04-02</dc:date>
			<dc:identifier>doi:10.1186/1472-6890-8-3</dc:identifier>
			
			
							
					<prism:publicationName>BMC Clinical Pathology</prism:publicationName>
					
			
							
					<prism:issn>1472-6890</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>3</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-02</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6890/8/5">
            
            <title>Comparison of DNA histograms by standard flow cytometry and image cytometry on sections in Barrett's adenocarcinoma</title>
			<description>Background:
The purpose of this study was to compare DNA histograms obtained by standard flow cytometry (FC) and high fidelity image cytometry on sections (ICS) in normal gastrointestinal mucosa and Barrett's adenocarcinoma (BAC).
Methods:
Archival formalin-fixed paraffin-embedded tissue blocks of 10 normal controls from 10 subjects and 42 BAC tissues from 17 patients were examined. DNA FC was performed using standard techniques and ICS was carried out by Automated Cellular Imaging System (ACIS). DNA ploidy histograms were classified into diploid with peak DNA index (DI) at 0.9&#8211;1.1, and aneuploid with peak DI > 1.1. DI values of aneuploid peaks were determined. Additionally, for DNA ICS, heterogeneity index (HI) representing DNA content heterogeneity, and histograms containing cells with DI > G2 were also identified.
Results:
All control samples were diploid by both FC and ICS analyses. In BAC, FC showed diploid peaks in 29%, diploid peaks with additional aneuploid or tetraploid peaks in 57%, and 14% of the samples, respectively. In contrast, ICS showed aneuploid peaks in all the cases with peak DI > 1.25; 37 cases had peak DI between 1.25 and 2.25; and 5 cases had peak DI > 2.25. HI values (mean &#177; SD) were 11.3 &#177; 1.1 in controls and 32.4 &#177; 8.5 in BAC (p &lt; 0.05). Controls had no G2 exceeding cells. However, 19/37 (51%) of the cases with primary peak DI &lt; 2.25 had cells exceeding 9N.
Conclusion:
ICS detects DNA aneuploidy in all BAC samples while FC missed the diagnosis of aneuploidy in 29%. In addition, ICS provides more information on HI and G2 exceeding rates.</description>
			<link>http://www.biomedcentral.com/1472-6890/8/5</link>		
			<dc:creator>Qin Huang, Chenggong Yu, Xiaoqi Zhang and Raj K Goyal</dc:creator>
			<dc:source>BMC Clinical Pathology 2008, 8:5</dc:source>
			<dc:subject>Number of accesses: 204</dc:subject>
			<dc:date>2008-05-30</dc:date>
			<dc:identifier>doi:10.1186/1472-6890-8-5</dc:identifier>
			
			
							
					<prism:publicationName>BMC Clinical Pathology</prism:publicationName>
					
			
							
					<prism:issn>1472-6890</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>5</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6890/8/6">
            
            <title>Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs</title>
			<description>Background:
Today, no objective criteria exist to differentiate between individual primary tumors and intra- or intermammary dissemination respectively, in patients diagnosed with two or more synchronous breast cancers. To elucidate whether these tumors most likely arise through clonal expansion, or whether they represent individual primary tumors is of tumor biological interest and may have clinical implications. In this respect, high resolution genomic profiling may provide a more reliable approach than conventional histopathological and tumor biological factors.
Methods:
32 K tiling microarray-based comparative genomic hybridization (aCGH) was used to explore the genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs, and was compared with histopathological and tumor biological parameters.
Results:
Based on global copy number profiles and unsupervised hierarchical clustering, five of ten (p = 1.9 &#215; 10-5) unilateral tumor pairs displayed similar genomic profiles within the pair, while only one of eight bilateral tumor pairs (p = 0.29) displayed pair-wise genomic similarities. DNA index, histological type and presence of vessel invasion correlated with the genomic analyses.
Conclusion:
Synchronous unilateral tumor pairs are often genomically similar, while synchronous bilateral tumors most often represent individual primary tumors. However, two independent unilateral primary tumors can develop synchronously and contralateral tumor spread can occur. The presence of an intraductal component is not informative when establishing the independence of two tumors, while vessel invasion, the presence of which was found in clustering tumor pairs but not in tumor pairs that did not cluster together, supports the clustering outcome. Our data suggest that genomically similar unilateral tumor pairs may represent a more aggressive disease that requires the addition of more severe treatment modalities, and underscores the importance of evaluating the clonality of multiple tumors for optimal patient management. In summary, our findings demonstrate the importance of evaluating the properties of both tumors in order to determine the most optimal patient management.</description>
			<link>http://www.biomedcentral.com/1472-6890/8/6</link>		
			<dc:creator>Sara Brommesson, G&#246;ran J&#246;nsson, Carina Strand, Dorthe Grabau, Per Malmstr&#246;m, Markus Ringn&#233;r, M&#229;rten Fern&#246; and Ingrid Hedenfalk</dc:creator>
			<dc:source>BMC Clinical Pathology 2008, 8:6</dc:source>
			<dc:subject>Number of accesses: 199</dc:subject>
			<dc:date>2008-07-10</dc:date>
			<dc:identifier>doi:10.1186/1472-6890-8-6</dc:identifier>
			
			
							
					<prism:publicationName>BMC Clinical Pathology</prism:publicationName>
					
			
							
					<prism:issn>1472-6890</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>6</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-10</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6890/8/1">
            
            <title>Preservation of biomolecules in breast cancer tissue by a formalin-free histology system</title>
			<description>Background:
The potential problems associated with the use of formalin in histology, such as health hazards, degradation of RNA and cross-linking of proteins are well recognized. We describe the utilization of a formalin-free fixation and processing system for tissue detection of two important biopredictors in breast cancer &#8211; estrogen receptor and HER2 &#8211; at the RNA and protein levels.
Methods:
Parallel sections of 62 cases of breast cancer were fixed in an alcohol-based molecular fixative and in formalin. Molecular fixative samples were processed by a novel formalin-free microwave-assisted processing system that preserves DNA, RNA and proteins. Formalin-fixed samples were processed using the conventional method. Estrogen receptor was assessed by immunohistochemistry and real-time PCR. HER2 was assessed by immunohistochemistry, FISH, CISH and real-time PCR.
Results:
The immunohistochemical reaction for estrogen receptor was similar in molecular- and formalin-fixed samples (Spearman Rank R = 0.83, p &lt; 0.05). Also HER2 result was similar to that of formalin-fixed counterparts after elimination of antigen retrieval step (Spearman Rank R = 0.84, p &lt; 0.05). The result of HER2 amplification by FISH and CISH was identical in the molecular fixative and formalin-fixed samples; although a shorter digestion step was required when using the former fixative. Real-time PCR for both estrogen receptor and HER2 were successful in all of the molecular fixative specimens.
Conclusion:
The formalin-free tissue fixation and processing system is a practical platform for evaluation of biomolecular markers in breast cancer and it allows reliable DNA and RNA and protein studies.</description>
			<link>http://www.biomedcentral.com/1472-6890/8/1</link>		
			<dc:creator>Mehdi Nassiri, Sharon Ramos, Hajir Zohourian, Vladimir Vincek, Azorides R Morales and Mehrdad Nadji</dc:creator>
			<dc:source>BMC Clinical Pathology 2008, 8:1</dc:source>
			<dc:subject>Number of accesses: 175</dc:subject>
			<dc:date>2008-01-29</dc:date>
			<dc:identifier>doi:10.1186/1472-6890-8-1</dc:identifier>
			
			
							
					<prism:publicationName>BMC Clinical Pathology</prism:publicationName>
					
			
							
					<prism:issn>1472-6890</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>1</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-01-29</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6890/2/2">
            
            <title>Effects of EDTA and Sodium Citrate on hormone measurements by fluorometric (FIA) and immunofluorometric (IFMA) methods</title>
			<description>Background:
Measurements of hormonal concentrations by immunoassays using fluorescent tracer substance (Eu3+) are susceptible to the action of chemical agents that may cause alterations in its original structure. Our goal was to verify the effect of two types of anticoagulants in the hormone assays performed by fluorometric (FIA) or immunofluorometric (IFMA) methods.
Methods:
Blood samples were obtained from 30 outpatients and were drawn in EDTA, sodium citrate, and serum separation Vacutainer&#174;Blood Collection Tubes. Samples were analyzed in automatized equipment AutoDelfia&#8482; (Perkin Elmer Brazil, Wallac, Finland) for the following hormones: Luteinizing hormone (LH), Follicle stimulating homone (FSH), prolactin (PRL), growth hormone (GH), Sex hormone binding globulin (SHBG), thyroid stimulating hormone (TSH), insulin, C peptide, total T3, total T4, free T4, estradiol, progesterone, testosterone, and cortisol. Statistical analysis was carried out by Kruskal-Wallis method and Dunn's test.
Results:
No significant differences were seen between samples for LH, FSH, PRL and free T4. Results from GH, TSH, insulin, C peptide, SHBG, total T3, total T4, estradiol, testosterone, cortisol, and progesterone were significant different between serum and EDTA-treated samples groups. Differences were also identified between serum and sodium citrate-treated samples in the analysis for TSH, insulin, total T3, estradiol, testosterone and progesterone.
Conclusions:
We conclude that the hormonal analysis carried through by FIA or IFMA are susceptible to the effects of anticoagulants in the biological material collected that vary depending on the type of assay.</description>
			<link>http://www.biomedcentral.com/1472-6890/2/2</link>		
			<dc:creator>Maria Beatriz F Kohek, Cassia Regina M Leme, Izabel T Nakamura, Suzimara A de Oliveira, Valeria Lando and Berenice B Mendonca</dc:creator>
			<dc:source>BMC Clinical Pathology 2002, 2:2</dc:source>
			<dc:subject>Number of accesses: 172</dc:subject>
			<dc:date>2002-05-23</dc:date>
			<dc:identifier>doi:10.1186/1472-6890-2-2</dc:identifier>
			
			
							
					<prism:publicationName>BMC Clinical Pathology</prism:publicationName>
					
			
							
					<prism:issn>1472-6890</prism:issn>
					
			
							
					<prism:volume>2</prism:volume>
					
			
							
					<prism:startingPage>2</prism:startingPage>
					
			
							
					<prism:publicationDate>2002-05-23</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6890/7/8">
            
            <title>Low specificity of HIV-testing on sputum specimens kept at ambient temperatures for 4 to 7 days: a blinded comparison</title>
			<description>Background:
HIV testing on sputum using the QraQuick HIV1/2&#174; assay has high sensitivity and specificity, and holds promise for application in tuberculosis surveys. Its performance under conditions that may occur during surveys in resource-poor countries is however, unknown. We assessed, in a blinded comparison with HIV serum testing, the sensitivity and specificity of the OraQuick&#174; assay for detecting HIV antibody in sputum specimens kept at ambient temperature for up to 7 days, with and without decontaminant.
Methods:
Paired sputum and blood specimens from consecutively diagnosed smear-positive tuberculosis patients were tested with OraQuick&#174; and 2 HIV-1/2 ELISA's. Sputum was tested within 24 hours of collection, split into 2 aliquots with and without addition of cetylpyridium chloride, and tested again after 4 and 7 days.
Results:
Complete data was available for 377/435 (87%) enrolled patients; 132 (35%) tested HIV positive on serum. The sensitivity of the sputum test was 94.7% (95% CI 89.4&#8211;97.8) on day 1, 93.2% on day 4 and 92.9% on day 7. The specificity was 92.9% (95% CI 88.9&#8211;95.8) on day 1, and declined to 76.7% on day 4 (p &lt; 0.001) and to 62.7% on day 7 (p &lt; 0.001). Adding cetylpyridium chloride further decreased the specificity to 67.8% on day 4 (p = 0.04) and to 49.6% on day 7 (p = 0.004).
Conclusion:
Transportation of sputum specimens at ambient temperatures for 4 days or more, and addition of decontaminant, strongly affect the specificity of the OraQuick&#174; assay. Unless applied within one day, this assay is not suitable for estimation of HIV-prevalence among tuberculosis patients in survey settings.</description>
			<link>http://www.biomedcentral.com/1472-6890/7/8</link>		
			<dc:creator>Saidi M Egwaga, Timothy M Chonde, Mecky I Matee, Sayoki G Mfinanga, Prosper E Ngowi, Fred Lwilla and Frank GJ Cobelens</dc:creator>
			<dc:source>BMC Clinical Pathology 2007, 7:8</dc:source>
			<dc:subject>Number of accesses: 165</dc:subject>
			<dc:date>2007-09-19</dc:date>
			<dc:identifier>doi:10.1186/1472-6890-7-8</dc:identifier>
			
			
							
					<prism:publicationName>BMC Clinical Pathology</prism:publicationName>
					
			
							
					<prism:issn>1472-6890</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>8</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-09-19</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6890/8/4">
            
            <title>Population-based study of diagnostic assays for Borrelia infection: comparison of purified flagella antigen assay (Ideia&#8482;, Dako Cytomation) and recombinant antigen assay (Liaison&#174;, DiaSorin)</title>
			<description>Background:
Testing for Borrelia-specific IgM and IgG-antibodies are often performed on a variety of poorly defined symptoms, and isolated IgM results are a frequent finding, which results in diagnostic uncertainty and further testing. We wanted to test the hypothesis that Borrelia-specific assays using recombinant antigens perform differently from assays based on purified flagella antigen.
Methods:
We compared the use of recombinant antigens (LIAISON&#174; DiaSorin, Saluggia, Italy) and purified flagella antigen (IDEIA&#8482; Borrelia, DakoCytomation, Glostrup, Denmark) in the assay for Borrelia-specific IgM and IgG-antibodies. The assays were tested on an unselected population of serum samples submitted from general practice. A total of 357 consecutive samples for analysis of Borrelia IgM and IgG antibodies. Furthermore, we analysed 540 samples for Borrelia-specific IgM or IgG antibodies first by the IDEIA&#8482; and, if they were positive, the samples were further analysed using the LIAISON&#174; assay. To verify the correctness of the patient's serological status, discrepant samples were analysed by line blots (EcoLine, Virotech).
Results:
In the consecutive series of 357 samples, the IgM assays detected 308 negative and 3 positive samples with concordant results. Compared with the line blot, the IDEIA&#8482; system produced 21 false-positive IgM results, whereas the LIAISON&#174; system produced only one false-positive IgM result. The IgG assays showed 1 positive and 328 negative concordant results. The LIAISON&#174; system produced 9 true IgG-positive samples that were not detected by the IDEIA&#8482; system, but the former produced 4 positive IgG results that were negative by line blot.
Conclusion:
Diagnostic assays based on flagella antigen seem to show more false-positive IgM and false-negative IgG results than assays based on recombinant antigens. The latter may reduce the number of presumably false-positive IgM results and identify more IgG-positive subjects, but this system also produces more false-positive IgG results.</description>
			<link>http://www.biomedcentral.com/1472-6890/8/4</link>		
			<dc:creator>Eskild Petersen, Martin Tolstrup, Francesco Capuano and Svend Ellermann-Eriksen</dc:creator>
			<dc:source>BMC Clinical Pathology 2008, 8:4</dc:source>
			<dc:subject>Number of accesses: 163</dc:subject>
			<dc:date>2008-04-18</dc:date>
			<dc:identifier>doi:10.1186/1472-6890-8-4</dc:identifier>
			
			
							
					<prism:publicationName>BMC Clinical Pathology</prism:publicationName>
					
			
							
					<prism:issn>1472-6890</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>4</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-18</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1472-6890/6/4">
            
            <title>Primary histologic diagnosis using automated whole slide imaging: a validation study</title>
			<description>Background:
Only prototypes 5 years ago, high-speed, automated whole slide imaging (WSI) systems (also called digital slide systems, virtual microscopes or wide field imagers) are becoming increasingly capable and robust. Modern devices can capture a slide in 5 minutes at spatial sampling periods of less than 0.5 micron/pixel. The capacity to rapidly digitize large numbers of slides should eventually have a profound, positive impact on pathology. It is important, however, that pathologists validate these systems during development, not only to identify their limitations but to guide their evolution.
Methods:
Three pathologists fully signed out 25 cases representing 31 parts. The laboratory information system was used to simulate real-world sign-out conditions including entering a full diagnostic field and comment (when appropriate) and ordering special stains and recuts. For each case, discrepancies between diagnoses were documented by committee and a "consensus" report was formed and then compared with the microscope-based, sign-out report from the clinical archive.
Results:
In 17 of 25 cases there were no discrepancies between the individual study pathologist reports. In 8 of the remaining cases, there were 12 discrepancies, including 3 in which image quality could be at least partially implicated. When the WSI consensus diagnoses were compared with the original sign-out diagnoses, no significant discrepancies were found. Full text of the pathologist reports, the WSI consensus diagnoses, and the original sign-out diagnoses are available as an attachment to this publication.
Conclusion:
The results indicated that the image information contained in current whole slide images is sufficient for pathologists to make reliable diagnostic decisions and compose complex diagnostic reports. This is a very positive result; however, this does not mean that WSI is as good as a microscope. Virtually every slide had focal areas in which image quality (focus and dynamic range) was less than perfect. In some cases, there was evidence of over-compression and regions made "soft" by less than perfect focus. We expect systems will continue to get better, image quality and speed will continue to improve, but that further validation studies will be needed to guide development of this promising technology.</description>
			<link>http://www.biomedcentral.com/1472-6890/6/4</link>		
			<dc:creator>John R Gilbertson, Jonhan Ho, Leslie Anthony, Drazen M Jukic, Yukako Yagi and Anil V Parwani</dc:creator>
			<dc:source>BMC Clinical Pathology 2006, 6:4</dc:source>
			<dc:subject>Number of accesses: 143</dc:subject>
			<dc:date>2006-04-27</dc:date>
			<dc:identifier>doi:10.1186/1472-6890-6-4</dc:identifier>
			
			
							
					<prism:publicationName>BMC Clinical Pathology</prism:publicationName>
					
			
							
					<prism:issn>1472-6890</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>4</prism:startingPage>
					
			
							
					<prism:publicationDate>2006-04-27</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
	<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
